1990 Volume 38 Issue 5 Pages 477-483
Ten patients with advanced bladder cancer (T 2-T 4) were treated by intra-arterial infusion, and the following pharmacokinetic parameters related to CDDP were studied:
#1) the pharmacokinetic behavior of intravenous (i. v.) and intra-arterial (i. a.) CDDP administration.
#2) the relationship between pharmacokinetic parameters (free Pt AUC) and clinical efficacy.
#3) the relationship between intratumoral concentration of platinum (Pt) and clinical efficacy.
Fifty to 120 mg/body of CDDP, 30 mg/body of ADM, and 20μg/body of angiotensin II were infused through both internal iliac arteries within 15 min and this protocol was repeated 1 to 3 times simultaneously with 30 Gy irradiation.
There was good correlation between the free Pt AUC and i.a. administered CDDP dose/creatinine clearance (r=0.728), and an even higher correlation for i. v. administration (r=0.918).The relationship between free Pt AUC and clinical efficacy was not significant. However, intratumoral Pt concentrations in clinically effective cases were higher than in ineffective cases, the critical Pt concentration being 2μg/g (wet tissue).
Intra-arterial CDDP infusion therapy has not only a regional, but also a systemic chemotherapeutic effect. It is noteworthly that the free Pt AUC was not significantly different for i. a. and i. v. administration.
